Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 9;37(35):3350–3358. doi: 10.1200/JCO.19.00345

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG 2. — Swimmer plots of treatment-free interval between immuno-oncology (IO) protocol therapy cessation and subsequent systemic anticancer (SSAC) therapy initiation for individual patients with advanced melanoma in the CheckMate 067 and 069 trials. Plotted is a random sample of 100 patients per treatment group for (A) nivolumab (NIVO) plus ipilimumab (IPI), (B) NIVO, and (C) IPI. The x-axis is oriented relative to cessation of IO protocol therapy and is truncated at 24 months before and 30 months after cessation. (*) Patients who remained on IO protocol therapy had therapy duration censored at the origin. (†) Treatment-free intervals were highlighted by setting the origin of the x-axis as the point of IO protocol therapy cessation and sorting the individual patients by duration of the treatment-free interval.